These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
446 related articles for article (PubMed ID: 12242156)
1. Stable suppression of tumorigenicity by virus-mediated RNA interference. Brummelkamp TR; Bernards R; Agami R Cancer Cell; 2002 Sep; 2(3):243-7. PubMed ID: 12242156 [TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA. Zhang YA; Nemunaitis J; Samuel SK; Chen P; Shen Y; Tong AW Cancer Res; 2006 Oct; 66(19):9736-43. PubMed ID: 17018633 [TBL] [Abstract][Full Text] [Related]
3. Retroviral gene transfer of dominant negative raf-1 mutants suppresses ha-ras-induced transformation and delays tumor formation. Heinicke T; Radziwill G; Nawrath M; Rommel C; Pavlovic J; Moelling K Cancer Gene Ther; 2000 May; 7(5):697-706. PubMed ID: 10830717 [TBL] [Abstract][Full Text] [Related]
4. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Sato M; Vaughan MB; Girard L; Peyton M; Lee W; Shames DS; Ramirez RD; Sunaga N; Gazdar AF; Shay JW; Minna JD Cancer Res; 2006 Feb; 66(4):2116-28. PubMed ID: 16489012 [TBL] [Abstract][Full Text] [Related]
5. [Study of growth inhibition of lung cancer cells by siRNA targeting mutant K-ras gene in vitro and in vivo]. Zhang ZP; Jiang GC; Yang F; Zhou ZL; Wang J Zhonghua Wai Ke Za Zhi; 2007 Sep; 45(18):1267-70. PubMed ID: 18067742 [TBL] [Abstract][Full Text] [Related]
6. Small interfering RNAs targeting mutant K-ras inhibit human pancreatic carcinoma cells growth in vitro and in vivo. Zhu H; Liang ZY; Ren XY; Liu TH Cancer Biol Ther; 2006 Dec; 5(12):1693-8. PubMed ID: 17106254 [TBL] [Abstract][Full Text] [Related]
7. [Reversal of malignant cell phenotype of human pancreatic adenocarcinoma cell line by recombinant retroviral vector expressing antisense Ki-ras]. Li H; Wang Z; Liu T Zhonghua Bing Li Xue Za Zhi; 1995 Oct; 24(5):288-91. PubMed ID: 8745475 [TBL] [Abstract][Full Text] [Related]
8. Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Zhang Y; Mukhopadhyay T; Donehower LA; Georges RN; Roth JA Hum Gene Ther; 1993 Aug; 4(4):451-60. PubMed ID: 8399492 [TBL] [Abstract][Full Text] [Related]
9. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Aoki K; Yoshida T; Sugimura T; Terada M Cancer Res; 1995 Sep; 55(17):3810-6. PubMed ID: 7641198 [TBL] [Abstract][Full Text] [Related]
10. Combined silencing of K-ras and Akt2 oncogenes achieves synergistic effects in inhibiting pancreatic cancer cell growth in vitro and in vivo. Shi XH; Liang ZY; Ren XY; Liu TH Cancer Gene Ther; 2009 Mar; 16(3):227-36. PubMed ID: 18949011 [TBL] [Abstract][Full Text] [Related]
11. Reversal of the phenotype by K-rasval12 silencing mediated by adenovirus-delivered siRNA in human pancreatic cancer cell line Panc-1. Chen LM; Le HY; Qin RY; Kumar M; Du ZY; Xia RJ; Deng J World J Gastroenterol; 2005 Feb; 11(6):831-8. PubMed ID: 15682475 [TBL] [Abstract][Full Text] [Related]
12. Use of retrovirus expression of interfering RNA to determine the contribution of activated K-Ras and ras effector expression to human tumor cell growth. Baines AT; Lim KH; Shields JM; Lambert JM; Counter CM; Der CJ; Cox AD Methods Enzymol; 2006; 407():556-74. PubMed ID: 16757353 [TBL] [Abstract][Full Text] [Related]
13. Growth inhibitory effect of anti-K-ras adenovirus on lung cancer cells. Alemany R; Ruan S; Kataoka M; Koch PE; Mukhopadhyay T; Cristiano RJ; Roth JA; Zhang WW Cancer Gene Ther; 1996; 3(5):296-301. PubMed ID: 8894248 [TBL] [Abstract][Full Text] [Related]
14. Transduction effect of antisense K-ras on malignant phenotypes in gastric cancer cells. Song JJ; Lee H; Kim E; Kim YS; Yoo NC; Roh JK; Kim BS; Kim J Cancer Lett; 2000 Aug; 157(1):1-7. PubMed ID: 10893435 [TBL] [Abstract][Full Text] [Related]
15. Suppression of pancreatic cancer by the dominant negative ras mutant, N116Y. Shichinohe T; Senmaru N; Furuuchi K; Ogiso Y; Ishikura H; Yoshiki T; Takahashi T; Kato H; Kuzumaki N J Surg Res; 1996 Dec; 66(2):125-30. PubMed ID: 9024823 [TBL] [Abstract][Full Text] [Related]
16. Loss of oncogenic ras expression does not correlate with loss of tumorigenicity in human cells. Plattner R; Anderson MJ; Sato KY; Fasching CL; Der CJ; Stanbridge EJ Proc Natl Acad Sci U S A; 1996 Jun; 93(13):6665-70. PubMed ID: 8692875 [TBL] [Abstract][Full Text] [Related]
17. A link between ras and metastatic behavior of tumor cells: ras induces CD44 promoter activity and leads to low-level expression of metastasis-specific variants of CD44 in CREF cells. Hofmann M; Rudy W; Günthert U; Zimmer SG; Zawadzki V; Zöller M; Lichtner RB; Herrlich P; Ponta H Cancer Res; 1993 Apr; 53(7):1516-21. PubMed ID: 8453616 [TBL] [Abstract][Full Text] [Related]
18. Nerve growth factor and enhancement of proliferation, invasion, and tumorigenicity of pancreatic cancer cells. Zhu Z; Kleeff J; Kayed H; Wang L; Korc M; Büchler MW; Friess H Mol Carcinog; 2002 Nov; 35(3):138-47. PubMed ID: 12410565 [TBL] [Abstract][Full Text] [Related]
19. Downregulation of PAR-4, a pro-apoptotic gene, in pancreatic tumors harboring K-ras mutation. Ahmed MM; Sheldon D; Fruitwala MA; Venkatasubbarao K; Lee EY; Gupta S; Wood C; Mohiuddin M; Strodel WE Int J Cancer; 2008 Jan; 122(1):63-70. PubMed ID: 17893871 [TBL] [Abstract][Full Text] [Related]
20. Ras interference as cancer therapy. Duursma AM; Agami R Semin Cancer Biol; 2003 Aug; 13(4):267-73. PubMed ID: 14563121 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]